Mirati Therapeutics Receives Positive Opinion from CHMP for KRAZATI (adagrasib) as a Targeted Treatment Option for Patients with Advanced Non-Small Cell Lung Cancer (NSCLC) with a KRASG12C Mutation Following a Re-Examination Procedure

SAN DIEGO, Calif. and ZUG, Switzerland, Nov. 10, 2023 -- (Healthcare Sales & Marketing Network) -- Mirati Therapeutics, Inc.® (NASDAQ: MRTX), a commercial stage biotechnology company, today announced that following a re-examination procedure, the Comp... Biopharmaceuticals, Oncology, Regulatory Mirati Therapeutics, KRAZATI, adagrasib, Non-Small Cell Lung Cancer
Source: HSMN NewsFeed - Category: Pharmaceuticals Source Type: news